Skip to main content
 

Andrew J. Griffith, M.D., Ph.D.

Deputy Director for Intramural Clinical Research
B.S., University of California, Davis, 1984
M.D., Ph.D., Yale University, 1992
Building 35, Room GF103
35A Convent Drive
Bethesda, MD 20892
301-402-2829

Dr. Andrew Griffith was appointed NIH deputy director for intramural clinical research (DDICR) in 2016. Andy continues his role as Scientific Director of the National Institute on Deafness and Other Communication Disorders (NIDCD), a position he has held since 2009. A well-known and respected clinician-scientist who has focused on genetic deafness, Andy also continues his role as chief of NIDCD’s Otolaryngology Branch.

As DDICR, Andy reports to the Deputy Director of Intramural Research, whom he assists and advises on a wide variety of activities related to clinical research within the entire intramural research program. These include development and implementation of policies related to the conduct and oversight of clinical research. Andy works with NIH Clinical Center leadership, the Office of Human Subjects Research Protections, the Office of Research Support and Compliance, and many other members of the intramural clinical research community across all institutes and centers.

Andy received his M.D. and Ph.D. degrees from Yale University. He completed an Otolaryngology-Head and Neck Surgery residency at the University of Michigan, where he also received fellowship training in the laboratory of Dr. Miriam Meisler in the Department of Human Genetics. In 1998, he joined the Intramural Research Program of NIDCD as a Senior Staff Fellow where he received additional training with Dr. Thomas Friedman in the Laboratory of Molecular Genetics. He has been a member of the Senior Medical Staff of the NIH Clinical Center since 1998 and an independent Investigator since 2000.

Andy’s research interests include all aspects, basic and clinical, of hereditary hearing loss. His clinical interests are the detection, diagnosis and management of the broad variety of genetic disorders of hearing which can occur in isolation or associated with disorders of other organs and tissues as part of a syndrome. He is a Principal Investigator on two clinical research protocols and continues to see patients enrolled in those studies. One of his protocols enrolls subjects with hearing loss associated with SLC26A4 mutations and enlargement of the vestibular aqueduct, the most common malformation of the inner ear in deaf children.

His laboratory works on the identification and characterization of genes underlying human hearing loss, including SLC26A4. They have to rely on mouse models to study the pathogenic mechanisms since tissues of the inner ear are inaccessible in living patients. His laboratory is developing Slc26a4 mutant mouse models to initiate pre-clinical studies of potential therapies. His laboratory also led pioneering studies that led to the discovery of the TMC gene family and the demonstration that the TMC1 and TMC2 genes encode protein components of the mechanoelectrical transduction channel of inner ear sensory cells.

Andy received the Presidential Early Career Award for Scientists and Engineers in 2002. He has served in many leadership roles across the NIH, and he currently serves on the editorial boards of the Journal of Medical Genetics and Otology & Neurotology


The page was last updated on Friday, September 8, 2017 - 3:26pm